Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 2Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Melanoma 1Liver Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cisplatin 136Radiotherapy 90Cetuximab 89pembrolizumab 65Fluorouracil 56Docetaxel 56Carboplatin 51Paclitaxel 44Radiotherapy, Intensity-Modulated 37Nivolumab 35durvalumab 19Erlotinib Hydrochloride 18Immunohistochemistry 16Radiation 13tremelimumab 12Gemcitabine 11Surgical Procedures, Operative 10Gene Expression Profiling 10Drug Therapy 10Biopsy 10Albumin-Bound Paclitaxel 10Chemotherapy, Adjuvant 9Capecitabine 9Bevacizumab 9atezolizumab 8Radiosurgery 8Polymerase Chain Reaction 8Neoadjuvant Therapy 8Ipilimumab 8130-nm albumin-bound paclitaxel 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Squamous Cell Carcinoma of Head and Neck × C188-9 compound × Clear all
NCT03195699 2025-03-21

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

Tvardi Therapeutics, Incorporated

Phase 1 Completed
64 enrolled
BreastDermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡